Myelin failure in multiple sclerosis: Breaking the spell of Notch

Nature Medicine

Volumn 8, Issue 10, 2002, Pages 1075-1076

  Hohlfeld, Reinhard ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; LEUKEMIA INHIBITORY FACTOR; MYELIN; NOTCH RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ALLERGIC ENCEPHALOMYELITIS; CELL TRANSPLANTATION; DEMYELINATION; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; IMMUNOMODULATION; INFLAMMATION; MULTIPLE SCLEROSIS; MYELINATION; NERVE FIBER DEGENERATION; NERVE LESION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REMYELINIZATION; SHORT SURVEY; STEM CELL;

ANIMALS; CALCIUM-BINDING PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MULTIPLE SCLEROSIS; MYELIN SHEATH; NEURONS; PROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS;

EID: 0036799564     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1002-1075     Document Type: Short Survey

References (13)

1. Lassmann, H., Brück, W. & Lucchinetti, C. Heterogeneity of multiple sclerosis pathogenesis: Implications for diagnosis and therapy. Trends Mol. Med. 7, 115-121 (2001)
2. John, R. et al. Multiple sclerosis: Re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nature Med. 8, 1115-1121 (2002).
3. Wolswijk, G. Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. Brain 125, 338-349 (2002).
4. Franklin, R.J.M. Why does remyelination fail in multiple sclerosis? Nature Rev. Neurosci. 3, 705-714 (2002).
5. Chang, A., Tourtellotte, W.W., Rudick, R. & Trapp, B.D. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 346, 165-173 (2002).
6. Charles, P. et al. Re-expression of PSA-NCAM by demyelinated axons: An inhibitor of remyelination in multiple sclerosis? Brain 125, 1972-1979 (2002).
7. Gorelik, L. & Flavell, R.A. Transforming growth factor-β in T-cell biology. Nature Rev. Immunol. 2, 46-53 (2002).
8. Wiendl, H. & Hohlfeld, R. Therapeutic approaches in multiple sclerosis: Lessons from failed and interrupted treatment trials. BioDrugs. 16, 183-200 (2002).
9. Osborne, B. & Miele, L. Notch and the immune system. Immunity 11, 653-663 (1999).
10. Butzkueven, H. et al. LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nature Med. 8, 613-619 (2002).
11. Linker, R.A. et al. CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytolkine as modulator in neuroinflammation. Nature Med. 8, 620-624 (2002).
12. Lucchinetti, C.F., Noseworthy, J.H., & Rodriguez, M. Promotion of endogenous remyelination in multiple sclerosis. Mult. Scler. 3, 71-75 (1997).
13. Halfpenny, C., Benn, T. & Scolding, N. Cell transplantation, myelin repair, and multiple sclerosis. Loncet Neurol, 1, 31-40 (2002)